Economic evaluation of chemotherapy. Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer

Anti-Cancer Drugs

Volumn 9, Issue 10, 1998, Pages 843-847

  Hillner, Bruce E ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 980170 ^*  (United States)

Author keywords

Breast neoplasm; Cost benefit analysis; Costs; Decision modeling; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH SERVICES RESEARCH; METHODOLOGY; PATHOLOGY; REVIEW; RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; META-ANALYSIS; RISK;

EID: 0032196872     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199811000-00003     Document Type: Article

References (23)

1. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. J Am Med Ass 1989; 262: 2879-86.
2. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. New York: Oxford University Press 1994.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988; 319: 1681-92.
4. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991; 324: 160-8.
5. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993; 16: 1-10.
6. Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node negative breast cancer? A cost-effectiveness analysis examining total and active life expectancy outcomes. J Clin Oncol 1993; 16: 11-20.
7. National Cancer Institute. Clinical Alert. May 16-18. Bethesda, MD: National Cancer Institute 1988.
8. Early Breast Cancer Trialists' Collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15; 71-85.
9. Rajagopal S, Goodman PJ, Tannock IF. Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials. J Clin Oncol 1994; 12: 1296-304.
10. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998; 16: 515-21.
11. Levine MN, Gafni A, Markham B, Macfarlane D. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med 1992; 117: 53-8.
12. Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 1996; 23: 43-50.
13. Trippoli S, Becagli P, Messori A. Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWiST method [letter]. Eur J Clin Pharmacol 1997; 53: 281-2.
14. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer [published erratum appears in Eur J Clin Pharmacol 1997; 51(5): 427]. Eur J Clin Pharmacol 1996; 51: 111-6.
15. Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-67.
16. Fisher B, Redmond C, Legault-Poisson S. et al. Post-operative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-18.
17. Hillner BE, Smith TJ. Estimating the efficacy and cost-effectiveness of tamoxifen (TAM) versus TAM plus adjuvant chemotherapy in post-menopausal node-positive breast cancer. A decision analysis model. Proc Am Soc Clin Oncol 1992; 11: 55 (abstr 46).
18. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347: 1066-71.
19. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
20. Hillner BE, Smith TJ, Desch CE. Efficacy- and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. J Am Med Ass 1992; 267: 2055-61.
21. Bates M, Lieu D, Zagari M, Spiers A, Williamson T. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clin Ther 1997; 19: 167-84.
22. Olivotto IA, Bajdik CD, Plenderleith IH, et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 1994; 330: 805-10.
23. National Cancer Institute Economic Conference. The integration of economic outcome measures into NCI-sponsored therapeutic trials. Monogr Natl Cancer Inst 1995; 19: 1-84.